DK1286686T3 - E-selectin til behandling og forebyggelse af slagtilfælde - Google Patents

E-selectin til behandling og forebyggelse af slagtilfælde

Info

Publication number
DK1286686T3
DK1286686T3 DK01939279T DK01939279T DK1286686T3 DK 1286686 T3 DK1286686 T3 DK 1286686T3 DK 01939279 T DK01939279 T DK 01939279T DK 01939279 T DK01939279 T DK 01939279T DK 1286686 T3 DK1286686 T3 DK 1286686T3
Authority
DK
Denmark
Prior art keywords
selectin
stroke
mammal
treatment
prevention
Prior art date
Application number
DK01939279T
Other languages
Danish (da)
English (en)
Inventor
John M Hallenbeck
Hidetaka Takeda
Maria Spatz
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK1286686T3 publication Critical patent/DK1286686T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01939279T 2000-05-24 2001-05-23 E-selectin til behandling og forebyggelse af slagtilfælde DK1286686T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20669300P 2000-05-24 2000-05-24
PCT/US2001/016583 WO2001089557A2 (en) 2000-05-24 2001-05-23 Methods for preventing strokes by inducing tolerance to e-selectin

Publications (1)

Publication Number Publication Date
DK1286686T3 true DK1286686T3 (da) 2007-11-19

Family

ID=22767527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01939279T DK1286686T3 (da) 2000-05-24 2001-05-23 E-selectin til behandling og forebyggelse af slagtilfælde

Country Status (11)

Country Link
US (2) US7261896B2 (https=)
EP (2) EP1286686B1 (https=)
JP (1) JP4986361B2 (https=)
AT (1) ATE367823T1 (https=)
AU (2) AU6481301A (https=)
CA (1) CA2410563C (https=)
DE (1) DE60129552T2 (https=)
DK (1) DK1286686T3 (https=)
ES (1) ES2292594T3 (https=)
PT (1) PT1286686E (https=)
WO (1) WO2001089557A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
WO2007028133A2 (en) * 2005-08-30 2007-03-08 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment and prevention of vascular dementia
WO2008045488A2 (en) * 2006-10-09 2008-04-17 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Treatment of inflammation, demyelination and neuronal/axonal loss
US7261896B2 (en) * 2000-05-24 2007-08-28 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Methods for preventing strokes by inducing tolerance to e-selectin
US20070244043A1 (en) * 2005-03-10 2007-10-18 Novavax, Inc. Recombinant E-selectin made in insect cells
US7939078B2 (en) * 2005-07-07 2011-05-10 Codman & Shurtleff Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue
WO2009038880A1 (en) * 2007-08-01 2009-03-26 Novavax, Inc. Novel e-selectin variant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
DK0482089T3 (da) 1989-07-14 1998-05-25 Autoimmune Inc Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
CA2070281C (en) 1989-12-20 2005-08-23 David Allen Hafler Improved treatment of autoimmune diseases by aerosol administration of auto antigens
AU651097B2 (en) 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
HUT69942A (en) 1990-10-15 1995-09-28 Brigham & Womens Hospital Treatment of autoimmun diseases by oral administration of autoantigenes
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
HU220357B (hu) * 1992-02-28 2001-12-28 Autoimmune Inc. Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
CA2133749A1 (en) 1992-04-09 1993-10-28 Howard L. Weiner Suppression of t-cell proliferation using peptide fragments of myelin basic protein
AU5080393A (en) 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
WO1995027499A1 (en) 1994-04-08 1995-10-19 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
AU695883B2 (en) 1994-04-08 1998-08-27 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines
US5891645A (en) * 1994-06-01 1999-04-06 Alexion Pharmaceuticals, Inc. Porcine E-selectin
GB9507768D0 (en) * 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US20010056073A1 (en) * 1998-07-21 2001-12-27 Ascher Shmulewitz Gene therapy method for revascularizing ischemic tissue
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US7897575B2 (en) * 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
US7261896B2 (en) * 2000-05-24 2007-08-28 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Methods for preventing strokes by inducing tolerance to e-selectin

Also Published As

Publication number Publication date
EP2295067A1 (en) 2011-03-16
DE60129552D1 (de) 2007-09-06
US7261896B2 (en) 2007-08-28
JP2004503471A (ja) 2004-02-05
CA2410563A1 (en) 2001-11-29
US20070253975A1 (en) 2007-11-01
CA2410563C (en) 2013-04-23
DE60129552T2 (de) 2008-04-17
ATE367823T1 (de) 2007-08-15
EP1286686B1 (en) 2007-07-25
EP1286686A2 (en) 2003-03-05
PT1286686E (pt) 2007-11-07
AU2001264813B2 (en) 2005-12-08
WO2001089557A2 (en) 2001-11-29
JP4986361B2 (ja) 2012-07-25
AU6481301A (en) 2001-12-03
ES2292594T3 (es) 2008-03-16
US20040009125A1 (en) 2004-01-15
WO2001089557A3 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
DE60131775D1 (de) Eine implantierbare oder einführbare vorrichtung zur abgabe therapeutischer mittel
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
DK1284740T3 (da) Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
AU2036902A (en) Methods and apparatus for stroke patient treatment
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
EP2279742A3 (en) Combinations for the treatment of immunoinflammatory disorders
ATE361730T1 (de) Vorrichtung für eine kryogene ganzkörperbehandlung eines patienten
IS7296A (is) Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
DE69923044D1 (de) Gewebebehandlungsmittel, Gewebe, Textildruckverfahren sowie Druck
DK1286686T3 (da) E-selectin til behandling og forebyggelse af slagtilfælde
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
GB0020504D0 (en) Therapeutic method
DK1229973T3 (da) Gynge til handikappede personer
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
AU5340801A (en) Therapeutic compounds and methods
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
PT1315496E (pt) Tratamento de desordens inflamatorias
DK0457848T3 (da) Behandling med væksthormon af lungedysfunktion og respirator-afhængighed
MXPA03000033A (es) Procedimiento de tratamiento de enfermedades vasculares perifericas, neuropatias perifericas y neuropatias autonomicas.
NO20042586L (no) Behandlingsfremgangsmate
ZA200204018B (en) Combination treatment for depression and anxiety.